Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
468.85 USD | -2.23% |
|
+2.01% | +16.43% |
Company Valuation: Vertex Pharmaceuticals Incorporated
Data adjusted to current consolidation scope
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
---|---|---|---|---|---|---|---|---|
Capitalization 1 | 61,457 | 55,834 | 74,127 | 104,849 | 103,707 | 120,399 | - | - |
Change | - | -9.15% | 32.76% | 41.44% | -1.09% | 16.1% | - | - |
Enterprise Value (EV) 1 | 54,798 | 48,309 | 63,349 | 93,630 | 97,591 | 110,769 | 105,016 | 98,712 |
Change | - | -11.84% | 31.13% | 47.8% | 4.23% | 13.5% | -5.19% | -6% |
P/E ratio | 23x | 24.4x | 22.5x | 29.3x | -194x | 31.2x | 26.6x | 22.9x |
PBR | 7.07x | 5.53x | 5.33x | 5.96x | 6.4x | 6.09x | 5.42x | 4.61x |
PEG | - | -2x | 0.5x | 3.51x | 2x | -0x | 1.6x | 1.4x |
Capitalization / Revenue | 9.9x | 7.37x | 8.3x | 10.6x | 9.41x | 10.1x | 9.16x | 8.4x |
EV / Revenue | 8.83x | 6.38x | 7.09x | 9.49x | 8.86x | 9.28x | 7.99x | 6.89x |
EV / EBITDA | 15.2x | 10.8x | 12.8x | 20.6x | 108x | 19.5x | 15.8x | 13.7x |
EV / EBIT | 15.7x | 11.1x | 13.2x | 21.4x | 140x | 20.5x | 16.6x | 14.3x |
EV / FCF | 18.3x | 20.1x | 16.1x | 28.1x | -123x | 26.2x | 21.8x | 17.5x |
FCF Yield | 5.46% | 4.99% | 6.2% | 3.56% | -0.81% | 3.82% | 4.58% | 5.72% |
Dividend per Share 2 | - | - | - | - | - | - | - | - |
Rate of return | - | - | - | - | - | - | - | - |
EPS 2 | 10.29 | 9.01 | 12.82 | 13.89 | -2.08 | 15.04 | 17.61 | 20.51 |
Distribution rate | - | - | - | - | - | - | - | - |
Net sales 1 | 6,206 | 7,574 | 8,931 | 9,869 | 11,020 | 11,936 | 13,146 | 14,332 |
EBITDA 1 | 3,601 | 4,470 | 4,941 | 4,556 | 902.8 | 5,671 | 6,645 | 7,198 |
EBIT 1 | 3,491 | 4,344 | 4,793 | 4,375 | 695.6 | 5,398 | 6,326 | 6,905 |
Net income 1 | 2,712 | 2,342 | 3,322 | 3,620 | -535.6 | 3,892 | 4,447 | 5,251 |
Net Debt 1 | -6,659 | -7,525 | -10,778 | -11,218 | -6,116 | -9,630 | -15,383 | -21,687 |
Reference price 2 | 236.34 | 219.60 | 288.78 | 406.89 | 402.70 | 468.85 | 468.85 | 468.85 |
Nbr of stocks (in thousands) | 260,038 | 254,252 | 256,691 | 257,683 | 257,529 | 256,797 | - | - |
Announcement Date | 01/02/21 | 26/01/22 | 07/02/23 | 05/02/24 | 10/02/25 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
---|---|---|---|---|---|---|
31.18x | 9.28x | 19.53x | -.--% | 120B | ||
37.3x | 12.31x | 28.09x | 0.75% | 712B | ||
15.04x | 4.2x | 11.56x | 3.34% | 378B | ||
27.26x | 6.59x | 13.78x | 3.42% | 340B | ||
16.85x | 6.08x | 12.14x | 3% | 305B | ||
14.15x | 3.48x | 8.6x | 3.84% | 259B | ||
17.15x | 4.63x | 11.21x | 3.26% | 237B | ||
22.3x | 4.15x | 12.2x | 2.28% | 219B | ||
10.68x | 3.46x | 7.48x | 3.86% | 209B | ||
22.58x | 5.78x | 11.22x | 3.25% | 159B | ||
Average | 21.45x | 6.00x | 13.58x | 2.7% | 293.74B | |
Weighted average by Cap. | 23.43x | 6.85x | 15.66x | 2.54% |
Year-on-year evolution of the PER
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- VRTX Stock
- Valuation Vertex Pharmaceuticals Incorporated
Select your edition
All financial news and data tailored to specific country editions

MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition